Beam Therapeutics Inc.
BEAM
$31.58
-$0.17-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -72.19% | 1,076.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -72.19% | 1,076.62% | |||
| Cost of Revenue | -88.86% | -9.56% | |||
| Gross Profit | 39.42% | 114.82% | |||
| SG&A Expenses | 6.66% | 20.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.62% | -3.63% | |||
| Operating Income | -514.59% | 86.24% | |||
| Income Before Tax | -138.61% | 316.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -138.61% | 316.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -138.61% | 316.71% | |||
| EBIT | -514.59% | 86.24% | |||
| EBITDA | -762.78% | 90.29% | |||
| EPS Basic | -138.46% | 316.08% | |||
| Normalized Basic EPS | -138.05% | 309.41% | |||
| EPS Diluted | -139.23% | 311.86% | |||
| Normalized Diluted EPS | -138.80% | 305.32% | |||
| Average Basic Shares Outstanding | 0.37% | 0.30% | |||
| Average Diluted Shares Outstanding | -1.59% | 2.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||